Close Menu

Clinical Services Lab

Short Reads: Mar 24, 2009

Premium

Life Technologies, J. Craig Venter Institute, BioNanomatrix, Nanosys, Geospiza, HDF Group, Pressure BioSciences, Cofactor Genomics, Ambry Genetics, Affymetrix, Navigenics, Enzymatics, New York State Department of Health, University of Washington

Navigenics decided to acquire Affy’s 10,000-square-foot Clinical Services Lab in Sacramento, Calif., after seeing an increase in the volume of orders for its genetic screening service. In addition to the advantages of having an internal CLIA lab, however, the consumer genomics firm will now have to navigate a complex regulatory environment.

Affy has decided to refocus its efforts on its core microarray platform and being an enabler for the broad adoption of microarrays across all genetic analysis markets, including CLIA lab services. Meanwhile, Navigenics takes over ownership of the lab as the volume of orders for its genetic screening service has increased.

Affy transferred ownership of the 10,000-square-foot Clinical Services Lab to Navigenics earlier this year though an increasing number of drug makers outsource their molecular diagnostic research needs to CLIA labs.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.